Cytogenix (fka CYGX)

[Paulness]

From Cytogenix website

We are conducting the remaining tests to assemble the data we believe the FDA will require to grant the Company Investigational New Drug Applications (IND) for the herpes and anti-bacterial compounds. We believe the herpes data set is complete enough to seek a pre-IND conference and are proceeding to schedule it. We are now conducting Minimum Inhibitory Concentration tests of the anti-microbial compounds. These will be followed by tests for toxicology, pharmacokinetics and pharmacodynamics. Given the success we have had using the anti-bacterial compounds in animals, we are confident that these additional tests will proceed successfully. When the tests are completed, we will seek a pre-IND meeting with the FDA for this product as well.